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Abstract
Purpose of Review This article reviews advances over the past 3 years in cardiac magnetic resonance (CMR) imaging in
pulmonary hypertension (PH). We aim to bring the reader up-to-date with CMR applications in diagnosis, prognosis, 4D flow,
strain analysis, T1 mapping, machine learning and ongoing research.
Recent Findings CMR volumetric and functional metrics are now established as valuable prognostic markers in PH. This imaging
modality is increasingly used to assess treatment response and improves risk stratification when incorporated into PH risk scores.
Emerging techniques such asmyocardial T1mappingmay play a role in the follow-up of selected patients.Myocardial strainmay be
used as an early marker for right and left ventricular dysfunction and a predictor for mortality. Machine learning has offered a
glimpse into future possibilities. Ongoing research of new PH therapies is increasingly using CMR as a clinical endpoint.
Summary The last 3 years have seen several large studies establishing CMR as a valuable diagnostic and prognostic tool in
patients with PH, with CMR increasingly considered as an endpoint in clinical trials of PH therapies. Machine learning ap-
proaches to improve automation and accuracy of CMR metrics and identify imaging features of PH is an area of active research
interest with promising clinical utility.
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Introduction
Pulmonary hypertension (PH) is a heterogeneous group of
diseases that cause an elevated pulmonary artery pressure [1,
2]. Chronic heart and lung diseases are the underlying causes
of most PH cases in the Western world [3] while living at
high-altitude and schistosomiasis infection are more common
in resource-limited countries [4]. Treatable causes include
chronic thromboembolic disease (CTEPH) and pulmonary ar-
terial hypertension (PAH) [5].
PH was historically considered as a rare, difficult to
diagnose and untreatable disease [6]. However, our under-
standing of the epidemiology, diagnosis and treatment of
PH has changed over the past two decades. Chronic co-
morbid cardiac and pulmonary diseases causing PH, such
as systemic hypertension and COPD, are increasingly
common in an ageing populat ion [7–9]. Recent
population-based studies suggest that the prevalence of
PH has increased by almost 30% over the last 30 years
[3]. PH is now estimated to have a prevalence of 1% of
the world’s population and might be the fourth most prev-
alent cardiovascular disease [6, 8].
The management of PH relies on ascertaining the diagno-
sis, discerning the underlying cause of PH, assessing disease
severity and monitoring response to treatment [1, 2]. The role
of cardiac magnetic resonance (CMR) in each of these key
aspects of PH management has been extensively studied and
is increasingly established in clinical practice.
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This article reviews significant advances over the past
3 years in CMR imaging in PH. We build on the previous
articles by Zitzman et al. and Swift et al. to bring the reader
up-to-date on the current developments in CMR applications
in PH [10, 11]. We aim to cover the latest articles about diag-
nosis, prognosis, 4D flow, strain analysis, T1 mapping, ma-
chine learning and interesting ongoing research.
Diagnosis
PH is diagnosed by right heart catheter (RHC). The haemo-
dynamic criteria for a diagnosis of PH from international
guidelines are an elevated mean pulmonary artery pressure
(mPAP) of ≥ 25 mmHg and pulmonary vascular resistance
(PVR) of ≥ 3 Wood units [5]. A new mPAP threshold of >
20 mmHg has recently been proposed as a more accurate
criterion, being two standard deviations above the normal
threshold [5].
In a breathless patient, PH is increasingly suggested on
common investigations such as chest radiography, echocar-
diogram or computer tomography [1, 12]. New advances in
noninvasive imaging techniques have helped to establish the
diagnosis of PH sooner in the course of the disease [13, 14].
Cardiac MRI has been used to estimate mPAP to provide
diagnosis through non-invasive means. A recent study devel-
oped regression models to predict mPAP based on cardiac
MRI [15]. A cohort of 600 patients who had both CMR and
RHC was retrospectively included. The cohort was divided in
half, the first half to derive the regression model and the sec-
ond half to validate its performance. CMR parameters includ-
ed in the linear regression model were the interventricular
septum angle (IVS), ventricular mass index (VMI) and black
blood slow flow. The model had a sensitivity of 93% and
specificity 79% of detecting PH, allowing for an accurate
non-invasive diagnosis. The model highly correlated with
mPAP and had good interobserver reproducibility. The au-
thors also recently updated their model in line with the new
suggested mPAP threshold of > 20 mmHg [16]. The same
group also developed a diagnostic and prognostic CMRmodel
for patients with PH secondary to chronic obstructive pulmo-
nary disease (COPD) [17]. Pulmonary artery (PA) indices of
the diastolic area and relative area change in addition to the
IVS and VMI were included in the COPD model. This model
had a 92% sensitivity and 80% specificity in detecting PH in
COPD patients. PA systolic and diastolic areas also had a high
diagnostic accuracy in detecting PH in patients with interstitial
lung disease [18]. CMR can be used as a one-stop study to
provide functional, aetiological and prognostic information
[19]. CMR showed a good correlation with RHC parameters
and had high sensitivity and specificity in identifying the un-
derlying causes of PH [19].
CMR-guided RHC is a recent technique that allows
performing RHC in a CMR suite. It combines the benefits of
radiation-free CMR information to haemodynamics in a single
sitting. CMR-guided RHC has a rare failure rate and an ac-
ceptable procedure time that is comparable to a standard CMR
study [20–22].
Prognosis and Therapy Response
PH is a chronic, progressive and mostly incurable disease with
high morbidity and mortality. A new diagnosis of PH in-
creases the risk of death at 1 year by sevenfold [3]. Mortality
is attributed to right heart failure resulting from the increased
afterload secondary to elevated pulmonary arterial pressures
[2]. PAH prognosis, however, has significantly improvedwith
the advancement of treatment, and the median survival has
increased from 3 to 7 years over the last 20 years [23, 24].
The ESC/ERS guidelines describe the prognostic factors
including imaging parameters in PAH [2]. Large right atrial
size and the presence of pericardial effusion on echocardio-
gram or CMR imaging feature as prognostic markers in the
ESC/ERS traffic light system representing low, intermediate
and high risk. There is a wider range of prognostic factors,
including the right ventricular metrics that are considered cru-
cially important in prognostication. Further work to determine
the most potent CMR prognostic factors and their incremental
value in prognostic equations is required.
The most recent statement on imaging and PH from the
Pulmonary Vascular Research Institute recommends cardiac
MRI to monitor right ventricular (RV) function [1]. CMR can
be used at follow-up to assess disease progression and treat-
ment response and provide prognostic information.
A recent systematic review, including 1,938 patients, has
shown that CMR is a powerful predictor of clinical worsening
and mortality in PH [25••]. In particular, worse RV function
and larger RV volume are associated with a worse outcome. A
large study in 2017 assessed CMR prognostic features in 576
patients [26••]. The study has shown that RV end-systolic
volume and pulmonary artery (PA) relative area change have
incremental prognostic value over clinical parameters.
Pulmonary artery stiffness assessed by a low relative area
change and distensibility is associated with a more severe
PH and a higher risk of mortality [26–28]. The prognostic
features in patients with connective tissue disease (CTD) were
shown to be different to other PAH subgroups. In CTD pa-
tients, metrics such as ventricular-vascular coupling (Ees/Ea)
and RV mass appear to be more significant than function and
volume [26••, 29–31]. New therapies have shown to improve
RV contractility and reduce RVmass in CTD PAH, and CMR
can play an important role in assessing their treatment re-
sponse [32, 33].
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Cardiac MRI assessment of the interventricular septal
(IVS) angle helps to differentiate pre- and postcapillary PH
from isolated postcapillary PH. An increased angle of ≥ 160°
is associated with pre- and postcapillary PH and with a poorer
prognosis [34]. In addition, increased trabeculation at the mar-
ginal IVS is associated with severe PH, reduced RV ejection
fraction (RVEF) and exercise tolerance [35, 36].
A large study has set the prognostic thresholds for CMR
indices [37••]. This study assessed the added value of CMR to
the validated prognostic calculators such as the Registry to
Evaluate Early and Long-Term PAH Disease Management
(REVEAL) and the modif ied French Pulmonary
Hypertension Registry (FPHR). The age- and sex-adjusted
RV end-systolic volume index improved prognostication
when combined with a risk score. The prognostic thresholds
will serve as an important guide for cardiac MRI risk stratifi-
cation in PAH. Notably, one of the most significant predictors
for a worse outcome in IPAHwas a background of evenminor
or mild parenchymal lung abnormality. A background of mild
fibrosis or emphysema was associated with a 5-year survival
of 22% compared to 78% in IPAH without any lung disease
[17, 38]. IPAH with lung disease has, therefore, been sug-
gested to be a separate phenotype of PAH [39].
Myocardial Strain Analysis
Strain analysis is an established CMR technique for the quan-
tification of myocardial deformation and assessment of wall
motion [40]. Feature tracking is one method of strain analysis
which follows cardiac borders throughout the cardiac cycle on
cine images (Fig. 1). Strain analysis in CMR uses similar
assumptions to speckle tracking on echocardiogramwith good
agreement between the two modalities [41, 42].
Biventricular strain is significantly impaired in PH and
could assist in the early detection of right and left heart dys-
function [43–45]. Besides, feature tracking technology has
been used to predict outcome in patients with PH. A reduced
RV circumferential and longitudinal strain rates were associ-
ated with an impaired RVEF and a significant predictor of
mortality [46]. The same holds true for the left ventricle
(LV) where reduced LV circumferential and longitudinal
strain rates in precapillary PH are associated with severely
impaired RVEF and a higher risk of death [47]. Impaired right
atrial (RA) strain and phasic function are a marker of disease
severity. Reduced RA strain is associated with decompensated
RV function and stiffness [48, 49]. The advancement of fully
automated myocardial strain analysis is likely to push its role
in future research in the diagnosis and prognosis of PH [50].
Myocardial Late Gadolinium Enhancement
Late gadolinium enhancement (LGE) is a CMR technique to
identify the areas of myocardial fibrosis. Gadolinium has para-
magnetic properties that shorten the myocardial T1 times. The
T1 shortening is proportional to the concentration of gadolin-
ium in the extracellular space. Gadolinium enhancement in the
normal myocardium clears out early. However, its clearance is
restricted in necrotic tissue due to the expansion of the extra-
cellular space and damage to the cellular membranes of the
myocytes [51].
Fig. 1 Images from right ventricular strain analysis in a patient with PH
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LGE is associated with poor outcome and increased mor-
tality in cardiomyopathies [52]. However, a study assessing
LGE in 124 PH patients found that LGE did not predict mor-
tality [53]. This finding confirms the results of two previous
studies that suggested no added prognostic information from
LGE in PH when added to other CMR parameters [54, 55].
Therefore, LGE in PH and particularly at the RV insertion
points or IVS appears to be a consequence of increased me-
chanical stress and RV remodelling and not a sign of RV
decompensation.
Myocardial T1 and Extracellular Volume
Mapping
Native myocardial T1 and extracellular volume (ECV)
mapping are novel biomarkers used in several cardiovas-
cular disorders to aid diagnostic, prognostic and therapeu-
tic decision-making [56]. Myocardial T1 mapping is a
pixel-by-pixel representation of the longitudinal relaxa-
tion times (T1) within a tissue [57]. T1 values provide
surrogate tissue characterisation data that are measured
on a standardised scale [58]. Assessing T1 post-
gadolinium can be used to estimate ECV [56, 59]. The
ECV is calculated by subtracting the T1 values of the
myocardium and blood pool pre- and post-contrast,
corrected for the haematocrit level [56]. Elevated T1 map-
ping values and ECV can indicate areas of oedema and
fibrosis in the myocardium [60, 61]. Several recent stud-
ies have looked into the clinical application of T1 map-
ping and ECV in PH [62–67]. T1 times are elevated in PH
and in particular at the RV insertion points and are asso-
ciated with an increased intraventricular septal angle and
LV eccentricity [62•, 65]. Increased T1 values are there-
fore thought to be related to RV dilatation and the resul-
tant shift of the septum towards the LV. The diagnostic
application in PH, however, remains limited. Although T1
looked promising for differentiating between healthy vol-
unteers and PH, the differences were much smaller in
patients without a PH diagnosis in a clinical setting [62].
A raised T1 value in PH is weakly correlated to RVEF
[62•, 64, 68]. However, T1 times did not predict mortality
in a large cohort of PH patients [62]. An elevated ECV in
PH patients with heart failure and preserved ejection frac-
tion was associated with RV dilatation, stiffness and re-
duced RV strain and therefore might play a role as a
marker for RV remodelling [67].
CMR also plays a role in CTEPH treatment response as-
sessment [69, 70]. Septal myocardial T1 mapping is elevated
in CTEPH patients [63] and reduces after treatment with bal-
loon pulmonary angioplasty [63, 71]. T1 mapping may, there-
fore, be utilised in CTEPH therapy monitoring.
Pulmonary MR Angiography and Perfusion
MR angiography (MRA) has a high spatial and low temporal
resolution that allows for the assessment of the pulmonary
vasculature. Perfusion MRI, on the other hand, has a low
spatial and a high temporal resolution that enables evaluation
of the capillary level tissue perfusion which makes it suitable
in the clinical assessment of CTEPH [72].
The diagnostic accuracy of dynamic contrast-enhanced
perfusion MRI in the diagnosis of CTEPH was shown to be
comparable to computed tomography pulmonary angiography
(CTPA) and perfusion single-photon emission tomography
(SPECT) [73]. Perfusion MRI identified all cases of CTEPH
and had comparable sensitivity and specificity to the other
modalities. Recent studies have shown that ventilation and
perfusion changes in CTEPH can be interrogated using
phase-resolved functional lungMRI without the need for con-
trast agents [74]. Perfusion MRI is likely to play an essential
role in the diagnostic pathway in centres that already perform
CMR for CTEPH patients.
4D Flow
Four-dimensional flow (4D flow) is an emergingMRI technology
that offers to circumvent issues with standard ultrasound imaging
in PH.Not only 4D flow allows 3Dvisualisation of vascular flow,
it also allows to make an accurate assessment of transvalvular or
intra-cavity flow [75]. In the setting of PH, 4D flow has been used
to assess the haemodynamic changes in the pulmonary circula-
tion. Abnormal flow patterns in the main pulmonary artery
(MPA), namely vortex formation, have been associated with
PH [76, 77]. The presence and ‘persistence time’ of the vortex
in the MPA are linearly associated with mPAP [78, 79] and can
be used to estimate mPAP. Another physiological vascular pa-
rameter characterised with 4D flow is MPA wall shear stress
(WSS), which has an impact on vascular remodelling [80]. 4D
flow-derived MPA WSS appears to be reduced in patients with
PH [80, 81]. Also, in patients with PH who have poor acoustic
windows for echocardiography, 4D flow can provide reliable
quantification of tricuspid regurgitation [82, 83]. 4D flow could
also provide clinically relevant RV diastolic assessment in PH
[84, 85]. To summarise, 4D flow MRI can provide several com-
plementary diagnostic information in the assessment of patients
presenting with suspected PH. Future studies need to evaluate the
incremental role of 4D flowMRI assessment in patients with PH.
Machine Learning
Machine learning (ML) uses algorithms to recognise patterns
in example data to make predict ive decisions in
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unprecedented data [86]. ML can classify the data based on
the differentiating patterns it has learnt [87, 88].
ML is likely to play an important role in PH [89]. Recent
approaches include automated segmentation [90, 91],
biventricular 3D model creation [92], computational models
and decision tree analysis [93], diagnosis [94••] and prognos-
tication [95••, 96].
ML has been used to analyse cardiac motion and predict
mortality based on reduced ventricular contraction [95••]. The
ML model was shown to improve outcome prediction com-
pared to conventional CMR measurements alone.
ML was used to identify diagnostic features on CMR and
classify them into PH or no PH [94••]. The discriminating
features were mapped onto CMR voxel space and were shown
as a visual overlay on the 4 chamber and short-axis images
(Fig. 2). Interestingly, this approach does not require segmen-
tation of the cardiac chambers, allowing for faster processing
and reduced segmentation-induced error. This study gives a
glimpse into the future of PH assessment that allows for rapid
and accurate CMR diagnoses. An exciting development
would be to ML methods utilised in predicting prognosis
and treatment response in PH.
Ongoing Research
Repeatability of CMR Measurements
The RESPIRE study aims to assess the reproducibility of
CMR measurements at follow-up. It will also compare the
repeatability of CMR to other endpoints such as walking and
blood tests. This study would help establish the evidence of
the usefulness of CMR as a monitoring tool and its sensitivity
to change [97].
CMR as Clinical Trial Endpoint
The REPAIR study is the first study to have MRI as a co-
primary endpoint [98••]. Four ongoing randomised controlled
trials, assessing beta-blockers, spironolactone, CXA-10 and
dehydroepiandrosterone, have defined CMR parameters as
an endpoint to evaluate treatment response [99–102]. A
single-arm study of treprostinil in PH has defined the change
in RV structure and function, on CMR compared to an echo-
cardiogram, as the primary treatment response outcome [103].
Follow-up CMR Assessment
A prospective study is aiming to recruit 180 incident cases of
PAH. Participants will have CMR and RHC at baseline and 6-
and 24-month follow-up. The aim is to determine poor prog-
nostic markers before decompensation occurs. This research
would be valuable in early risk stratification as current studies
include patients with more advanced stages of the disease
[104].
CTEPH Diagnosis and Screening
CHANGE-MRI is a large European multicentre study that
aims to compare dynamic contrast-enhanced MRI compared
to VQ-SPECT in people with suspected CTEPH. This study is
anticipated to set the standard for MRI in the diagnostic algo-
rithm for CTEPH [105].
Conclusions
The last 3 years have seen several large studies examining the
clinical utility of CMR in patients with PH. Evidence confirms
the potential for CMR to provide diagnostic and prognostic
information that can guide clinical practice. CMR has been
utilised in clinical trials to detect the impact of PH therapies
and is increasingly proposed as a trial endpoint. Machine
learning approaches to improve automation and accuracy of
CMR metrics and identify imaging features of PH shows po-
tential and is likely to improve the clinical utility of CMR
imaging.
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Fig. 2 Machine learning feature map. Features compatible with PH are in
red and non-PH features are in green
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